SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin gets EIR from USFDA for Mandideep Unit-2 manufacturing facility

01 Nov 2023 Evaluate

Lupin has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Mandideep Unit-2 manufacturing facility. The EIR was issued post the last inspection of the facility conducted from August 7 to August 11, 2023. The inspection closed with the facility receiving an inspection classification of ‘No Action Indicated’ (NAI).

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

2396.50 -23.65 (-0.98%)
01-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1865.95
Dr. Reddys Labs. 1339.35
Cipla 1456.95
Zydus Lifesciences 1108.85
Lupin 2396.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: